Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dabigatran Etexilate→

Dabigatran Etexilate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
211915-06-9
Molecular formula
C34H41N7O5
Molecular weight
627.73 g/mol
Drug class
Oral direct thrombin inhibitor prodruganticoagulant
Mechanism of action
Dabigatran etexilate is an orally administered prodrug converted by esterases to dabigatran, a direct, competitive inhibitor of free and clot-bound thrombin. Thrombin inhibition prevents fibrin formation and thrombin-mediated platelet activation.
Indications / reported uses
  • Prevention of stroke and systemic embolism in eligible adults with non-valvular atrial fibrillation
  • Treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) after initial parenteral anticoagulation, and reduction of recurrent DVT/PE risk
  • Primary prevention of venous thromboembolic events after hip replacement surgery in adults; paediatric indications and dosing are product-label specific

Sources: US DailyMed — PRADAXA (dabigatran etexilate) · EMA EPAR — Pradaxa · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dabigatran Etexilate Environmental Risk Assessment (ERA) (the Dabigatran Etexilate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.